Explore the history of COPD and the evolution of disease concepts, treatment strategies, patient outcomes, pulmonary rehabilitation and clinical management.
Comparison of COPD exacerbator classification systems (GOLD E vs Frequent Exacerbator) using proteomics and metabolomics to identify biological differences and biomarkers.
The ROME proposal for COPD exacerbations classification offers a new approach to assess severity and predict outcomes, improving clinical decision-making
Conferencia sobre el manejo proactivo de la EPOC centrada en el infradiagnóstico, el control clínico y el seguimiento estructurado del paciente.
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
